Zobrazeno 1 - 10
of 260
pro vyhledávání: ''
Publikováno v:
Journal of Clinical Oncology. 41:1331-1338
PURPOSE Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA). The purpose
Autor:
Trenton Reinicke, Justin F. Gainor, Marissa N Bruno, Henning Willers, Erika Nakajima, Anand S. Dighe, Yi-Bin Chen, Vivek Naranbhai, Leyre Zubiri, Aleigha Lawless, Brittany Y Bertaux, Aditya Bardia, Kerry L. Reynolds, Rebecca R. Saff, Jocelyn R. Farmer, Kerri St. Denis, A. John Iafrate, Elizabeth Niehoff, Joan How, Mustafa Sakhi, Grace Kirkpatrick, Arthur Y. Kim, Wilfredo-Garcia Beltran, Alejandro B. Balazs, Alexander Gavralidis, Caroline Barabell, Monica A Jackson, C. Bowes, Lailoo A Perriello, Amir T. Fathi, Andrew M. Brunner, Evan C. Lam, Gabriela S. Hobbs, Grace Hambelton, Christian N Nambu, Kimberly G. Blumenthal, Julia Thierauf, Laura Spring, Elyssa Denault, Claire A. Pernat, Steven J. Isakoff, Ryan J. Sullivan, Cristhian J Berrios-Mairena, Jennifer L Peterson, Lindsey Mortensen, Onosereme Ofoman
Publikováno v:
Journal of Clinical Oncology. 40:12-23
PURPOSE The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer are poorly understood. METHODS We performed a prospective cohort study of adults with solid-organ or hematologic cancers to evaluate anti–SARS-CoV-2 immuno
Autor:
Meena Thayu, A. Roshak, Jose Manuel Trigo, Jong Seok Lee, Keunchil Park, Santiago Viteri, Ramaswamy Govindan, Natasha B. Leighl, Ji-Youn Han, Paul Mitchell, Nahor Haddish-Berhane, James Chih-Hsin Yang, Chee Khoon Lee, Roland Elmar Knoblauch, Patricia Lorenzini, Byoung Chul Cho, Dawn Millington, Nicolas Girard, Alexander I. Spira, Tsung-Ying Yang, Rachel E. Sanborn, Eric B. Haura, J.C. Curtin, Matthew G Krebs, Pilar Garrido, Koichi Goto, Sang-We Kim, Dong Wan Kim, Karen L. Reckamp, Ki Hyeong Lee, Joshua Bauml, Joshua K. Sabari, Catherine A. Shu, John Xie
Publikováno v:
Park, K, Haura, E, Leighl, N B, Mitchell, P, Shu, C, Girard, N, Viteri, S, Han, J-Y, Kim, S-W, Lee, C K, Sabari, J, Spira, A, Yang, T-Y, Kim, D-W, Lee, K H, Sandborn, R, Trigo, J, Goto, K, Lee, J-S, Yang, J C-H, Govindan, R, Bauml, J M, Garrido, P, Krebs, M, Reckamp, K, Xie, J, Curtin, J, Haddish-Berhane, N, Roshak, A, Millington, D, Lorenzini, P, Thayu, M, Knoblauch, R & Cho, B C 2021, ' Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.21.00662
PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with
Autor:
Vernon K. Sondak, Andrew Poklepovic, Nikhil I. Khushalani, Jason J. Luke, Sunil Babu, Sigrun Hallmeyer, Zeynep Eroglu, Mario R. Velasco, Emily F. Higgs, Bruce Brockstein, Daniel J Olson, Thomas Krausz, Madhuri Bajaj, Timothy Carll, Riyue Bao, Jose Lutzky, Theodore Karrison, Brian W. Labadie, Thomas F. Gajewski, Yuanyuan Zha
Publikováno v:
J Clin Oncol
PURPOSE Combination of antiprogrammed cell death protein-1 (PD-1) plus anti–cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial anti-PD-1 and p
Autor:
Erin Jensen, M. Catherine Pietanza, Andrew G. Robinson, Martin Reck, Rina Hui, Julie R. Brahmer, Nir Peled, Ticiana A. Leal, Jonathan W. Riess, Andrea Fülöp, Mary O'Brien, Delvys Rodriguez-Abreu, Katsuyuki Hotta, Ali Tafreshi, Bin Zhao, Suman Rao, Tibor Csőszi, Maya Gottfried, Sinead Cuffe
Publikováno v:
Journal of Clinical Oncology. 39:2339-2349
PURPOSE We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738 ) is an open-label, randomized controlled trial of pembroli
Autor:
Lu Xu, Delvys Rodriguez-Abreu, Te Chun Hsia, Mehmet Ali Nahit Sendur, Perran Fulden Yumuk, A. Samkari, Irfan Cicin, Olivier Molinier, Bilal Piperdi, Keynote Investigators, Adrian Langleben, Dae Ho Lee, Balazs Medgyasszay, Francisco Orlandi, Michael Boyer, Ticiana A. Leal, Raffaele Califano, Gregory A. Otterson, Martin Reck, Keunchil Park, Nopadol Soparattanapaisarn
Publikováno v:
Journal of Clinical Oncology. 39:2327-2338
PURPOSE Pembrolizumab monotherapy is standard first-line therapy for metastatic non–small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 50% without actionable driver mutations. It is not known whet
Autor:
Neil S. Horowitz, Panagiotis A. Konstantinopoulos, Stephanie Morrissey, Roxanne Quinn, Carolyn N. Krasner, Ursula A. Matulonis, Alexi A. Wright, Jennifer Taylor Veneris, Nabihah Tayob, Susan Schumer, Niya Xiong, Gabriela West, Joyce F. Liu, Susana M. Campos
Publikováno v:
Journal of Clinical Oncology. 39:1531-1539
PURPOSEUterine serous carcinoma (USC) is a distinct histologic subtype of endometrial cancer, with molecular characteristics suggesting frequent cell-cycle dysregulation paired with a high level of oncogene-driven replication stress. Adavosertib is a
Autor:
Roberto Hegg, Hiroji Iwata, G. Kurteva, Michael F. Press, Miguel Izquierdo, Olga Burdaeva, Sergei Tjulandin, Sergio Daniel Simon, Seock-Ah Im, In Hae Park, Sarah Kenny, William J. Gradishar, L. S. Williams, Stephen R. D. Johnston, Severine Sarp
Publikováno v:
J Clin Oncol
PURPOSE Human epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved clinical benefit in HER2-positive, hormone receptor (HR)–positive metastatic breast cancer (MBC) versus ET alone. Dual HER2 blockade enhances cli
Autor:
Shisheng Tan, Sanjun Cai, Ji Zhu, Zhen Zhang, Yaqun Zhu, Hongyan Zhang, Xin Wang, Chen Zhang, Tao Zhang, Jianhui Jia, Jialin Yang, Xinchen Sun, Hui Zhang, Wei Zhang, F. Xia, Juefeng Wan, Yuanyuan Zhao, Anwen Liu, Junxin Wu, Luying Liu, Juying Zhou, Lijun Shen, Gang Cai
Publikováno v:
Journal of Clinical Oncology
PURPOSE Differentiating the irinotecan dose on the basis of the uridine diphosphate glucuronosyltransferase 1A1 ( UGT1A1) genotype improves the pathologic complete response (pCR) rate. In this study, we further investigated preoperative irinotecan co
Autor:
Polina Kaplan, Javier de la Serna, Malgorzata Wach, Sean Dolan, Phillip L. Campbell, Jae Hoon Lee, Martin Simkovic, Árpád Illés, Iryna Kraychok, Eric J. Avery, Wojciech Jurczak, Andrzej Pluta, Abraham Jacob, Tomas Kozak, Gerardo Musuraca, Daniel Lysák, Wei Liang, Priti Patel, Cheng Quah, Paolo Ghia
Publikováno v:
Journal of Clinical Oncology. 38:2849-2861
PURPOSE Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was evaluated in this global, multicenter, randomized, open-label, phase III study in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). MET